Key Highlights

  • ImmuPharma is attracting renewed investor attention as development of its Kapiglucagon programme advances toward the next stage.
  • The company has selected specialist Manufacturing partners for both the Kapiglucagon active pharmaceutical ingredient and drug product.
  • A bioanalytical contract research organisation has also been selected to support the programme.
  • The company is simultaneously seeking commercial opportunities for its P140/Lupuzor™ autoimmune platform.
  • ImmuPharma completed a £6.47 million fundraising in April 2026, substantially strengthening its Balance Sheet compared with the end of 2025.
  • The latest share-price move comes as investors assess whether the company's expanding development pipeline can generate significant future licensing or Partnership value.

Why ImmuPharma Is in Focus Today

ImmuPharma plc has become a notable small-cap healthcare stock after LSE:IMM rose 13.75% on 14 September 2026.

The company is attracting attention because its development pipeline has entered an increasingly important phase.

ImmuPharma is advancing two principal value drivers: P140, also known as Lupuzor™, an autoimmune therapeutic platform, and Kapiglucagon, a peptide-based drug candidate focused on metabolic disease.

The current Investment story is therefore broader than the company's historic focus on Lupuzor.

Kapiglucagon has become increasingly important during 2026 as ImmuPharma moves through its IND-enabling programme and builds the manufacturing and analytical infrastructure needed for future clinical development.

At the same time, the company is pursuing potential partnering opportunities for P140, creating the possibility of a licensing transaction that could materially change its financial position.

Why LSE:IMM Shares Rose 13.75% on 14 September 2026

LSE:IMM is shown up 13.75% on 14 September 2026, making ImmuPharma one of the stronger-performing small-cap healthcare names in the day's market activity.

There is no clear evidence of a single new clinical-trial announcement released today that independently explains the entire gain.

Instead, the move appears to reflect renewed investor interest around a series of developments that have accumulated through 2026.

The most important is the continuing advancement of Kapiglucagon.

In May, ImmuPharma initiated its IND-enabling programme for Kapiglucagon. In June, it appointed Bachem as the manufacturing partner for the programme's active pharmaceutical ingredient. In July, Thermo Fisher Scientific was selected as the drug-product contract development and manufacturing organisation. In August, ImmuPharma announced the selection of a bioanalytical contract research organisation.

Taken together, these developments demonstrate that the programme is moving from early development toward a more structured regulatory and clinical-development pathway.

For a small biotech company, that progression can generate significant speculative interest because each successful development potentially reduces execution uncertainty.

Kapiglucagon Is Becoming a Major Growth Catalyst

Kapiglucagon is a novel peptide-based therapeutic candidate being developed for metabolic diseases.

The programme is particularly important because metabolic medicine represents a large and rapidly developing pharmaceutical market.

ImmuPharma's strategy is to advance Kapiglucagon through the IND-enabling stage, generating the data and manufacturing package required to support a future clinical programme.

The selection of established specialist partners is therefore important.

Bachem has been appointed to manufacture the Kapiglucagon API, while Thermo Fisher Scientific has been selected to support drug-product development and manufacturing.

The company has also appointed a specialist bioanalytical CRO to support the programme.

These appointments do not establish clinical efficacy, but they indicate that ImmuPharma is investing in the infrastructure necessary to advance the candidate toward human clinical development.

P140 and Lupuzor Remain Central to the Investment Case

Although Kapiglucagon is gaining prominence, P140/Lupuzor™ remains an important part of ImmuPharma's potential valuation.

P140 is a peptide-based therapy being developed for autoimmune and inflammatory diseases. ImmuPharma describes the programme as an approach designed to restore immune balance rather than broadly suppress immune activity.

The company has previously reported seven completed Clinical Trials demonstrating the safety profile of P140.

The next major value driver is therefore not simply another laboratory result but the ability to establish a commercial development and partnering pathway.

During 2026, ImmuPharma indicated that it was progressing discussions with potential partners for its P140 technology platform, including discussions under confidentiality agreements.

A successful licensing or strategic partnership transaction could potentially provide non-dilutive funding, development resources and external validation for the technology.

That possibility remains one of the biggest reasons investors continue to watch LSE:IMM.

The £6.47 Million Fundraise Strengthened the Position

Another important development behind the current investment story is ImmuPharma's April 2026 fundraising.

The company completed a £6.47 million fundraise at 6p per share, comprising a £6 million subscription through Lanstead Capital and an additional retail offer.

This substantially increased the company's financial resources compared with the £1.4 million cash balance reported at 31 December 2025.

The additional capital is particularly important because biotechnology development is cash-intensive.

Kapiglucagon requires manufacturing, analytical testing, regulatory preparation and eventually clinical development. P140 also requires ongoing research and partnering activity.

The strengthened balance sheet therefore provides ImmuPharma with greater flexibility to advance its programmes without relying immediately on another major financing.

However, the fundraising also increased the number of shares in issue, meaning investors must consider dilution when assessing the long-term value of the business.

Recent Shareholder Activity Adds Another Angle

On 10 September 2026, Lanstead Capital Investors reduced its voting interest in ImmuPharma from approximately 17.99% to 14.67%.

This represents a substantial holding but also indicates a reduction in one of the company's major shareholder positions.

The development is not necessarily a negative signal about the underlying pipeline. Large shareholders can adjust positions for numerous reasons, including financing structures, Portfolio Management and Liquidity requirements.

Nevertheless, investors are likely to monitor further changes in major holdings because ImmuPharma has a relatively small Market Capitalisation and a substantial proportion of its shares can influence market liquidity.

What Investors Are Watching Next

The most important catalyst for LSE:IMM is continued advancement of Kapiglucagon.

Investors will be watching for further progress toward completion of the IND-enabling programme and any subsequent regulatory developments.

Kapiglucagon development: Completion of the required preclinical, manufacturing and analytical work would move the programme closer to human clinical development.

Regulatory progress: Future interaction with regulators and preparation of the clinical package could provide important milestones.

P140 partnering: A licensing or strategic partnership could become a transformational event for the company.

Clinical development: Investors will ultimately want to see Kapiglucagon and P140 progress into meaningful clinical programmes.

Cash position: The April fundraising provides additional resources, but continued development will consume capital.

Strategic partnerships: New collaborations could reduce funding requirements while providing external validation of ImmuPharma's technology.

Why Investors Are Watching LSE:IMM

The attraction of ImmuPharma is the potential mismatch between its relatively small Market Value and the possible value of its development pipeline.

The company is currently valued as a small-cap biotechnology business, yet successful development or partnering of either P140 or Kapiglucagon could potentially create substantially greater commercial opportunities.

That is the fundamental reason the stock can react sharply to relatively small pieces of positive news.

A successful licensing deal for P140, for example, could potentially provide upfront payments, milestone income or development support.

Similarly, successful advancement of Kapiglucagon could establish another strategic asset in an attractive metabolic-disease market.

However, these outcomes remain prospective.

Financial Performance Remains a Key Risk

ImmuPharma is not currently a profitable commercial pharmaceutical company.

Its 2025 full-year results showed a £1.8 million loss, although this was an improvement from the £2.5 million loss reported in 2024.

Research and development expenditure was approximately £1.3 million.

The April 2026 fundraising substantially improved available resources, but continued Drug Development will require significant capital.

This means the market is likely to remain highly sensitive to funding announcements, development costs and the timing of potential licensing transactions.

Key Risks

The biggest risk is clinical-development failure.

Kapiglucagon has not yet established commercial efficacy, while P140 still requires a viable future development and commercialisation pathway.

There is also regulatory risk. Successful completion of an IND-enabling programme does not guarantee regulatory clearance to begin clinical trials.

Another major risk is funding. Although the April fundraising strengthened the balance sheet, future clinical development could require significantly more capital.

Shareholder dilution is therefore an ongoing consideration.

There is also partnering risk. The investment thesis for P140 includes the potential for a licensing or strategic partnership, but there is no guarantee that negotiations will result in an attractive transaction.

Finally, small-cap biotech shares can be highly volatile because valuation depends heavily on future milestones rather than established earnings.

Why Today's 13.75% Rally Matters

The 13.75% gain on 14 September 2026 highlights how sensitive LSE:IMM remains to changes in investor expectations.

The company now has multiple potential catalysts rather than relying exclusively on one programme.

Kapiglucagon is moving through IND-enabling development, manufacturing partners have been appointed and bioanalytical support has been established.

Meanwhile, P140 offers a separate potential commercialisation route through partnering.

This creates a potentially attractive catalyst-rich period for shareholders.

But the market will ultimately require tangible evidence of progress.

The next major re-rating would likely need to come from a regulatory milestone, clinical-development progression, a meaningful partnership or other evidence that one of the programmes can generate substantial future value.

Bottom Line

ImmuPharma plc is up 13.75% on 14 September 2026, putting LSE:IMM firmly back in focus among speculative healthcare and biotechnology investors.

The latest rise appears to reflect renewed interest in the company's expanding development pipeline, particularly Kapiglucagon and the potential commercialisation of P140/Lupuzor™.

Kapiglucagon has made meaningful development progress during 2026. ImmuPharma initiated its IND-enabling programme, appointed Bachem for API manufacturing, selected Thermo Fisher Scientific for drug-product development and manufacturing, and subsequently appointed a bioanalytical CRO.

That sequence of developments is important because it indicates that the programme is moving toward a potential clinical-development stage.

P140 provides another potential catalyst. The company has been pursuing discussions with prospective partners, creating the possibility of a licensing transaction that could bring external funding and validation.

The £6.47 million fundraising completed in April 2026 has also provided greater financial flexibility, although future clinical development could still require substantial additional capital.

For investors, LSE:IMM is therefore a high-risk, potentially high-reward biotech proposition. The 13.75% gain is an important sentiment signal, but the longer-term value creation will depend on regulatory progress, clinical development, successful partnering and the company's ability to fund its pipeline.